Gilead’s Once-Daily HIV Combo Receives Priority Status; Accelerates Race With GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
The fixed-dose co-formulation of Viread/Emtriva has an estimated user fee deadline of Sept. 12; a decision on GSK’s combo is expected in August. Results from a study of Viread, Emtriva and Sustiva are due by year end, Gilead said.
You may also be interested in...
Merck, Bristol, Gilead Are In Discussions For Combo HIV Therapy
Merck, Bristol-Myers Squibb, and Gilead are in discussion to develop a co-packaged version of three different AIDS drugs for use in the developing world
GSK Expects To Launch Once-Daily HIV Combo Product Ahead Of Gilead
GlaxoSmithKline believes its future once-daily combination of Epivir and Ziagen will be stronger than Gilead's pending HIV combination
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.